SynthesisThe pharmacogenomics journal2018
Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Synthesis in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy.The pharmacogenomics journal · 2021 · on this mapPooled it
- Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis.European journal of clinical pharmacology · 2021Pooled it
- Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.Clinical pharmacology and therapeutics · 2019Pooled it
- The pharmacogenetics of rosuvastatin and implications for treatment: a systematic review.PharmacogenomicsPooled it
- The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.Scientific reports · 2020Trial
- Uncovering Coenzyme Q10-Related Genetic Determinants of Statin-Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program.Clinical pharmacology and therapeutics · 2026Article
- Optimizing pharmacogenomic clinical decision support: a usability study of epic's Genomic-Indicators.BMC pharmacology & toxicology · 2026Article
- Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses.European cardiology · 2026Review
- The application of genetic testing technology in kidney transplantation: precision matching, non-invasive monitoring and personalized management.Frontiers in immunology · 2025Review
- Effects of statins on sarcopenia with focus on mechanistic insights and future perspectives.Frontiers in pharmacology · 2025Review
- SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin-induced rhabdomyolysis: A case report.British journal of clinical pharmacology · 2025Article
- Decoding the Intricacies of Statin-Associated Muscle Symptoms.Current rheumatology reports · 2024Review
- Estimation of the benefit from pre-emptive genotyping based on the nationwide cohort data in South Korea.Clinical and translational science · 2024Review
- Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions.Advances in laboratory medicine · 2023Article
- Clinician Response to Pharmacogenetic Clinical Decision Support Alerts.Clinical pharmacology and therapeutics · 2023Article
- Article
- Predictive Value ofGenes · 2023Article
- Prescriber Adoption of SLCO1B1 Genotype-Guided Simvastatin Clinical Decision Support in a Clinical Pharmacogenetics Program.Clinical pharmacology and therapeutics · 2023Article
- How to Implement a Pharmacogenetics Service at your Institution.Journal of the American College of Clinical Pharmacy : JACCP · 2022Article
- Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous studies have illustrated the relationship between SLCO1B1 T521C polymorphism and statin-induced myopathy risk; however, this association is not consistent. Three electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched from inception to October 2017 to identify potential studies. The summary odds ratios (ORs) with 95% confidence intervals (CIs) were calculated from different genetic models by using a random-effects model. Fourteen studies comprising 3265 myopathy patients and 7743 controls were included. The summary ORs suggested that 521CC (OR: 2.31; 95% CI: 1.15-4.63; P = 0.019), 521TC (OR: 1.34; 95% CI: 1.02-1.76; P = 0.034), and 521CC + TC (OR: 1.82; 95% CI: 1.32-2.51; P < 0.001) were associated with a greater risk of statin-induced myopathy than 521TT. The higher incidence of statin-induced myopathy was found to be significantly correlated with the C allele compared with the T allele (OR: 1.89; 95% CI: 1.36-2.62; P < 0.001). In addition, we observed that 521CC + TC was associated with an increased risk of myopathy in individuals who received simvastatin (OR: 2.35; 95% CI: 1.08-5.12; P = 0.032) or rosuvastatin (OR: 1.69; 95% CI: 1.07-2.67; P = 0.024) when compared with 521TT. The 521C allele was associated with a greater risk of cerivastatin-induced myopathy than the T allele (OR: 1.95; 95% CI: 1.47-2.57; P < 0.001). The findings of this study indicated that SLCO1B1 T521C was associated with a significantly higher risk of statin-induced myopathy, especially for simvastatin, rosuvastatin, and cerivastatin. Future studies should be conducted in subjects receiving specific types of drugs, and any potential adverse events need to be explored.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.